Adocia SA/€ADOC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Adocia SA
Adocia SA is a clinical-stage biotechnology company headquartered in Lyon, France, specializing in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Founded in 2005 by Gérard Soula and his sons Olivier and Rémi, the company has developed a proprietary BioChaperone® technology platform designed to enhance the efficacy and safety of therapeutic proteins. Adocia's clinical pipeline includes products such as BioChaperone Lispro, an ultra-rapid insulin formulation, and BioChaperone Combo, a combination of basal and rapid-acting insulins. The company has established a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize its products in China and other Asian and Middle Eastern territories. (,)
- Ticker
- €ADOC
- Sector
- Health
- Primary listing
- PAR
- Employees
- 80
- Headquarters
- Lyon, France
- Website
- www.adocia.com
Adocia SA Metrics
BasicAdvanced
€88M
-
-€0.83
0.39
-
Price and volume
Market cap
€88M
Beta
0.39
52-week high
€9.50
52-week low
€3.24
Average daily volume
418K
Financial strength
Current ratio
0.884
Quick ratio
0.826
Long term debt to equity
-1.292
Total debt to equity
-1.836
Interest coverage (TTM)
-13.05%
Profitability
EBITDA (TTM)
-14.272
Gross margin (TTM)
-471.03%
Net profit margin (TTM)
-533.07%
Operating margin (TTM)
-495.54%
Effective tax rate (TTM)
0.08%
Revenue per employee (TTM)
€40,000
Management effectiveness
Return on assets (TTM)
-37.94%
Return on equity (TTM)
610.56%
Valuation
Price to revenue (TTM)
28.091
Price to book
-19.09
Price to tangible book (TTM)
-19.09
Price to free cash flow (TTM)
-14.586
Free cash flow yield (TTM)
-6.86%
Free cash flow per share (TTM)
-0.301
Growth
Revenue change (TTM)
-76.84%
Earnings per share change (TTM)
40.05%
3-year revenue growth (CAGR)
-34.97%
10-year revenue growth (CAGR)
-23.59%
3-year earnings per share growth (CAGR)
-29.57%
10-year earnings per share growth (CAGR)
13.19%
What the Analysts think about Adocia SA
Analyst ratings (Buy, Hold, Sell) for Adocia SA stock.
Analyst projections of the future price of Adocia SA stock.
Adocia SA Financial Performance
Revenues and expenses
Adocia SA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.